NeoGenomics, Inc. Restructuring Charges
NeoGenomics, Inc. (NEO) reported Restructuring Charges of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-02-17
- NeoGenomics, Inc. restructuring charges for the quarter ending 2024-03-31 was $2.40M, a 48.80% decline year-over-year.
- NeoGenomics, Inc. restructuring charges for the quarter ending 2023-12-31 was $1.21M, a 73.32% decline year-over-year.
- NeoGenomics, Inc. restructuring charges for the quarter ending 2023-09-30 was $2.13M.
- NeoGenomics, Inc. restructuring charges for the quarter ending 2023-06-30 was $3.07M.
- NeoGenomics, Inc. restructuring charges for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- NeoGenomics, Inc. restructuring charges for fiscal 2024 was $6.66M, a 39.95% decline from fiscal 2023.
- NeoGenomics, Inc. restructuring charges for fiscal 2023 was $11.09M, a 145.53% increase from fiscal 2022.
- NeoGenomics, Inc. restructuring charges for fiscal 2022 was $4.52M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-17 | |||
| 2024-12-31 | $6.66M 10-K · filed 2026-02-17 | |||
| 2024-03-31 | $2.40M 10-Q · filed 2024-04-30 | $3.60M derived: sum of 2 quarters · filed 2026-02-17 | $5.73M derived: sum of 3 quarters · filed 2026-02-17 | $8.80M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $3.33M derived: sum of 2 quarters · filed 2026-02-17 | $6.40M derived: sum of 3 quarters · filed 2026-02-17 | $11.09M 10-K · filed 2026-02-17 |
| 2023-09-30 | $2.13M 10-Q · filed 2023-11-06 | $5.20M derived: sum of 2 quarters · filed 2023-11-06 | $9.88M 10-Q · filed 2023-11-06 | $14.40M derived: sum of 4 quarters · filed 2024-04-30 |
| 2023-06-30 | $3.07M 10-Q · filed 2023-08-08 | $7.76M 10-Q · filed 2023-08-08 | $12.27M derived: sum of 3 quarters · filed 2024-04-30 | $12.27M derived: sum of 4 quarters · filed 2024-04-30 |
| 2023-03-31 | $4.68M 10-Q · filed 2024-04-30 | $9.20M derived: sum of 2 quarters · filed 2024-04-30 | $9.20M derived: sum of 3 quarters · filed 2024-04-30 | $9.20M derived: sum of 4 quarters · filed 2024-04-30 |
| 2022-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $4.52M derived: sum of 2 quarters · filed 2024-02-20 | $4.52M derived: sum of 3 quarters · filed 2024-02-20 | $4.52M 10-K · filed 2024-02-20 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-20 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |